Volume | 63,668 |
|
|||||
News | - | ||||||
Day High | 12.38 | Low High |
|||||
Day Low | 11.92 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Alto Neuroscience Inc | ANRO | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
12.38 | 11.92 | 12.38 | 11.96 | 12.00 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
1,315 | 63,668 | US$ 12.12 | US$ 771,775 | - | 11.68 - 24.00 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:00:00 | 2,030 | US$ 11.96 | USD |
Alto Neuroscience Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
319.38M | 26.79M | - | 0 | -36.31M | -1.36 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Alto Neuroscience News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ANRO Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.99 | 13.63 | 11.77 | 12.45 | 85,958 | -0.03 | -0.25% |
1 Month | 14.36 | 15.07 | 11.68 | 13.11 | 100,538 | -2.40 | -16.71% |
3 Months | 14.24 | 18.3499 | 11.68 | 14.53 | 154,719 | -2.28 | -16.01% |
6 Months | 22.00 | 24.00 | 11.68 | 15.65 | 202,303 | -10.04 | -45.64% |
1 Year | 22.00 | 24.00 | 11.68 | 15.65 | 202,303 | -10.04 | -45.64% |
3 Years | 22.00 | 24.00 | 11.68 | 15.65 | 202,303 | -10.04 | -45.64% |
5 Years | 22.00 | 24.00 | 11.68 | 15.65 | 202,303 | -10.04 | -45.64% |
Alto Neuroscience Description
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients¿ brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates. |